An investigational new agent called tasquinimod may help increase survival in men with metastatic prostate cancer

Continue Reading

This oral agent has been found to extend progression-free survival by a mean of 7.6 months compared with 3.3 months for placebo.

John Schieszer has the latest on this new agent in today’s Medical Minute.